Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HC2-LC1
- Development stage
- Preclinical
- Lead developer
- Mayo Clinic
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
HC2-LC1 is a humanized single-chain variable fragment (scFv) antibody being developed by the Mayo Clinic for the treatment of COVID-19. Derived from a murine anti-Ebola virus glycoprotein (GP) scFv antibody that exhibited cross-reactivity due to structural similarities between the Ebola GP and the SARS-CoV-2 spike (S) protein, HC2-LC1 was humanized using computer modeling. It specifically targets the receptor-binding domain (RBD) of the SARS-CoV-2 spike glycoprotein, neutralizing the virus and preventing infection of host cells. Preclinical studies indicate that HC2-LC1 retains the binding affinity, virus neutralization, and cell-protective properties of its parental murine antibody.
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on HC2-LC1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HC2-LC1.